Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Up 230.8% in December

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 8,600 shares, an increase of 230.8% from the December 15th total of 2,600 shares. Based on an average daily volume of 362,400 shares, the days-to-cover ratio is presently 0.0 days.

Oncotelic Therapeutics Trading Up 22.8 %

Shares of OTCMKTS:OTLC opened at $0.04 on Tuesday. The company’s fifty day simple moving average is $0.03 and its 200 day simple moving average is $0.03. Oncotelic Therapeutics has a 12 month low of $0.02 and a 12 month high of $0.05. The firm has a market cap of $14.22 million, a price-to-earnings ratio of -3.50 and a beta of -0.27. The company has a quick ratio of 0.01, a current ratio of 0.01 and a debt-to-equity ratio of 0.28.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.